ProShare Advisors
TNGX icon

ProShare Advisors’s Tango Therapeutics TNGX Stock Holding History

ProShare Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$725K Buy
23,190
+1,066
+5% +$26.4K ﹤0.01% 904
2026
Q1 		$463K Sell
22,124
-3,260
-13% -$45.4K ﹤0.01% 1107
2025
Q4 		$225K Buy
25,384
+9,154
+56% +$78.9K ﹤0.01% 1642
2025
Q3 		$136K Sell
16,230
-3,545
-18% -$24K ﹤0.01% 1783
2025
Q2 		$101K Buy
19,775
+4,570
+30% +$11.3K ﹤0.01% 1875
2025
Q1 		$20.8K Sell
15,205
-3,319
-18% -$8.15K ﹤0.01% 2035
2024
Q4 		$57.2K Buy
18,524
+3,178
+21% +$14.8K ﹤0.01% 2162
2024
Q3 		$118K Buy
15,346
+2,772
+22% +$26.5K ﹤0.01% 1852
2024
Q2 		$108K Sell
12,574
-2,595
-17% -$20.1K ﹤0.01% 1654
2024
Q1 		$120K Buy
15,169
+1,263
+9% +$13.5K ﹤0.01% 1788
2023
Q4 		$138K Buy
13,906
+2,324
+20% +$20.2K ﹤0.01% 1728
2023
Q3 		$130K Buy
11,582
+56
+0.5% +$341 ﹤0.01% 1582
2023
Q2 		$38.3K Sell
11,526
-76
-0.7% -$273 ﹤0.01% 1796
2023
Q1 		$45.8K Sell
11,602
-1,691
-13% -$9.81K ﹤0.01% 1681
2022
Q4 		$96.4K Buy
+13,293
New +$93.5K ﹤0.01% 1657

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ProShare Advisors's TNGX Position: Q2 2026 in Review

ProShare Advisors increased its Tango Therapeutics (TNGX) stake by 4.8% in Q2 2026, buying an estimated $26.4K and bringing the position to 23,190 shares worth $725K. The position accounts for ﹤0.01% of the portfolio, ranked #904.

ProShare Advisors first reported a position in TNGX in Q4 2022 and has held it in 15 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • ProShare Advisors held 23,190 shares of Tango Therapeutics worth $725K as of Q2 2026.
  • ProShare Advisors bought 1,066 Tango Therapeutics shares in Q2 2026, an estimated $26.4K.
  • Tango Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #904 holding.
  • ProShare Advisors first reported a position in Tango Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.